Almost Complete Response with a Single Administration Ac-225-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

Creative Commons License

ALAN SELÇUK N., Demirci E., Ocak M., Toklu T., Ergen S., KABASAKAL L.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, cilt.31, sa.2, ss.139-141, 2022 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4274/mirt.galenos.2022.64497
  • Dergi Adı: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.139-141
  • Anahtar Kelimeler: Ac-225 targeted alpha therapy, neuroendocrine tumors, peptide receptor radionuclide therapy
  • İstanbul Üniversitesi Adresli: Evet

Özet

Neuroendocrine tumors (NETS) are being seen increasingly frequently, and the only known curative treatment method is surgical resection. Peptide receptor radionuclide therapy (PRRT) is a treatment option that the most contributes to progression-free survival and overall survival in metastatic cases.beta-emitting radionuclides are traditionally used for PRRT. Nowadays, alpha particle-emitting radionuclides are being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy. In this case; in a patient with NET diagnosis who had multiple (>50) lesions in the abdomen, almost all the lesions disappeared with a single dose application. This paper aims to present a case in which we observed the efficacy of Ac-225-DOTATATE treatment, which is an alpha treatment.